A lyophilized peptide is a dry glassy solid, and the reactions that degrade peptides in water run slowly or not at all without water. That is why manufacturers ship lyophilized peptides at ambient temperature, why approved freeze-dried peptide drugs are labelled for controlled room-temperature storage for their whole shelf life, and why the standard accelerated stability condition for pharmaceuticals is 40 °C for six months. None of the published figures below is a measurement of a research vial.

Why a dry solid is more stable than a solution

Almost every route by which a peptide degrades needs water as a reactant or needs molecules mobile enough to meet oxygen, metals or each other; the residue-level chemistry is in Freeze-thaw, aliquots and the residues that oxidize. Remove the water and the molecules are locked in an amorphous glass in which they can barely rotate, let alone react. How that glass is made is described in What lyophilized means.

Two properties of that glass govern how well it holds. The first is residual moisture, the small amount of water left after drying. A 2025 study of freeze-dried glucagon and insulin formulations in Pharmaceutics states the principle plainly: "Low residual moisture is critical for ensuring the long-term stability of freeze-dried biopharmaceuticals." Residual moisture is what the Karl Fischer line on a certificate reports. The second is the glass transition temperature, the point at which the solid softens and molecular mobility jumps. The same study reports that an arginine-containing glucagon formulation with a glass transition near 45 °C collapsed at the three-month point of its stability study, with what the authors call "a sharp decline" in purity, while trehalose-based formulations "effectively maintained the purity" of insulin and glucagon "over three months at 40 °C."

Moisture therefore does double damage: it plasticises the glass, lowering its transition temperature, and it feeds the reactions. Bachem's guideline says peptides "tend to be hygroscopic" and that absorbed moisture "reduces the overall peptide content and may also decrease stability." That is why the vial is sealed, why it ships with desiccant, and why cold glass exposed to humid air collects condensation.

The reference conditions: ICH Q1A(R2)

Stability claims for pharmaceuticals are made against a defined set of conditions set out in ICH guideline Q1A(R2), adopted by FDA in November 2003. For the general case:

The accelerated condition, 40 °C at 75% relative humidity for six months, is the standard stress test. A product that survives it without "significant change" supports a room-temperature shelf life; one that does not is tested at the intermediate condition and labelled for cooler storage. A summer parcel that sits in a warm depot for a day or two is a small fraction of a six-month accelerated study.

What published data show for lyophilized peptides

Approved freeze-dried peptide products are labelled for room temperature. The FDA label for EGRIFTA SV, a lyophilized tesamorelin product, specifies controlled room-temperature storage. Tesamorelin is a 44-residue analogue of growth hormone-releasing hormone, GHRH(1-44). Amphastar's lyophilized glucagon kit label likewise specifies controlled room-temperature storage.

A room-temperature shelf life on an approved label is the output of a full ICH stability program on that formulation, and it is the clearest published statement that a lyophilized peptide, properly formulated and dried, does not need a cold chain to remain within specification.

Lyophilized peptide mixtures held a month at room temperature. A 2024 paper in the International Journal of Peptide Research and Therapeutics from the University of Virginia melanoma vaccine group reports that their lyophilized mixtures of six and twelve peptides "retain stability, purity, and amino acid sequence identity for up to five years when stored at -80°C," and that "when stored at +4°C or at room temperature for up to one month, 17 of the 18 peptides remained stable. The only change for the remaining peptide was an increase in an oxidized methionine residue."

Freeze-dried glucagon and insulin at 40 °C for three months. In the 2025 Pharmaceutics study above, freeze-dried samples were held at 40 °C and 50 °C and analysed by RP-HPLC at one, two and three months. With amorphous excipients (trehalose or hydroxyethyl starch) purity was maintained over three months at 40 °C; formulations with crystalline mannitol, or with a low glass transition, lost purity. The variable was the excipient, not the temperature alone.

Manufacturer guidance. Bachem and LifeTein both describe ambient shipping of the dry solid as routine and reserve frozen conditions for long-term holding of the lyophilizate; LifeTein ships in sealed bags to limit moisture uptake. Neither manufacturer regards ambient transit as a stability event.

A patent example. A NoNO Inc. patent on a lyophilized formulation of the peptide TAT-NR2B9c defines a stable formulation as one in which "no more than 10%, preferably 5%, of peptide is degraded" over at least a week to three months, and describes the formulation as designed for "storing a lyophilized formulation sample ... for at least a week at room temperature." The patent's stability comparison was run at −20 °C and 40 °C for one week. It reports the comparison as a bar graph, so no figure is quoted here.

What changes first

The published data agree on the order in which a lyophilized peptide goes wrong.

1. Moisture uptake. The first measurable change in a vial that has been opened, or whose seal has failed, is a rise in water content, which lowers the glass transition and starts the chemistry. Bachem's note that absorbed moisture lowers peptide content is the certificate-level symptom.
2. Oxidation of methionine, then tryptophan and cysteine. The one change the vaccine group saw after a month at room temperature was oxidized methionine. Sequences with Met, Trp or Cys are the ones to read with that in mind; those residues are called out in How to read a peptide sequence.
3. Physical change in the cake. Collapse, shrinkage or a glassy melted look means the solid passed its glass transition, which for a poorly formulated cake can be as low as the mid-40s °C. A collapsed cake is an analytical warning before it is a chemical one.
4. Hydrolysis and deamidation. These need water and time, and in a dry cake they are the slowest of the routes.

Why summer shipping of a powder is a different question from shipping a solution

A solution in transit carries all the water the degradation chemistry needs, so its temperature history is the whole story; that is the world the 28-day convention belongs to, as described in Where the 28 days number comes from. A sealed lyophilized vial carries almost none. Its transit hazard is not a day at 35 °C but a broken seal, a wet parcel or a cake that was never dried properly in the first place, all of which show up as moisture. The site's shipping page describes lyophilized material as shipping in an insulated mailer with gel packs. For a lyophilized vial, what matters after a warm parcel is whether the seal is intact and what the certificate's Karl Fischer line says, not what the thermometer read.

What the published data cannot answer is the specific case: a particular research lot, without stabilising excipients, after a particular transit. The approved products above were formulated for their shelf life, and the vaccine peptides were a defined mixture in a defined buffer before drying. A research vial of a single peptide with its counter-ion and residual moisture is a simpler system, and only a measurement of that lot says how it fared.

Sources

• Q1A(R2) Stability Testing of New Drug Substances and Products, Guidance for Industry, FDA/ICH, November 2003
• EGRIFTA SV prescribing information, Theratechnologies, DailyMed, revised February 2024
• Glucagon kit prescribing information, Amphastar Pharmaceuticals, DailyMed, revised March 2025
• Ashkani J et al., Stability of Multi-Peptide Vaccines in Conditions Enabling Accessibility in Limited Resource Settings, International Journal of Peptide Research and Therapeutics 30(4), 2024
• Gao H et al., The Detrimental Effects of Crystalline Excipients: How They Jeopardize the Long-Term Stability of Freeze-Dried Polypeptide Formulations, Pharmaceutics 17(12):1543, 2025
• Handling and Storage Guidelines for Peptides, Bachem, accessed 2026-09-21
• Handling and Storage of Synthetic Peptides, LifeTein, accessed 2026-09-21
• Lyophilized formulation of TAT-NR2B9C with acetylation scavenger, US Patent 10,206,878, NoNO Inc., 2019
• Akbarian M et al., Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins, Pharmaceutics 14(11):2533, 2022